Corporate Action Story Puts Concord Biotech in Play: Share Price Opened Gap-Down at ₹1,540.20, and Here Is the Arithmetic

Why CONCORDBIO is being traded today

The corporate action story around Concord Biotech (CONCORDBIO) has the stock at ₹1,560.30, +1.79% on the last session, with the NSE board read at the close of the last trading session on Wednesday, 23 September 2026. What the tape shows: the session opened below the previous close, and gaps that are not filled in the first hour usually take the rest of the day to repair.

The market is closed at the time of writing (Wednesday, 06:05 pm IST); the levels below are the close of the Wednesday, 23 September 2026 session.

The story in five lines

• Where it trades: Concord Biotech is at ₹1,560.30, +27.90 (+1.79%) versus the previous close of ₹1,560.30.
• Why it is moving: a corporate-action story — one business desk filed on the company in the last few hours.
• Today's band: ₹1,518.90 to ₹1,568.00, against an open of ₹1,540.20 — the stock is defending its opening print.
• Twelve-month context: 6.43% below the ₹1,668 high and 58.09% above the ₹987 low, so the stock sits in the upper part of its own range.
• Participation: turnover is running at 1.0x the twenty-day average, which is ordinary flow — the move lacks a volume endorsement so far.
• What to watch: the record date and the ex-date, since buying after the ex-date does not carry entitlement even though the price has already adjusted.

The corporate action angle

The reason Concord Biotech is on the desks today is a corporate action story — reported by one desk so far, with the headlines linked below. Corporate actions have a mechanical price effect: eligibility is set by the record date and the price adjusts on the ex-date, so a move around the announcement is about signalling, not value transfer.

Live price snapshot

Record date, ex-date and what actually gets you paid

Corporate actions are the one area of the market where the price move is arithmetic rather than opinion. Entitlement is decided by the record date: whoever appears in the register on that date receives the dividend, bonus or split entitlement. Because settlement takes a day, the last day to buy with entitlement is the day before the ex-date — buy on or after the ex-date and the payout belongs to the seller.

On the ex-date the price adjusts down by roughly the entitlement, so an apparent fall is not a loss for existing holders. For bonus issues and splits the adjustment is proportional and the holding value is unchanged; only the number of shares and the per-share price change. Buybacks are different again — they return cash by reducing share count, so the effect is on future per-share earnings rather than on a one-off payout.

For CONCORDBIO, the dates in the exchange filing are the operative facts; the current ₹1,560.30 print already reflects whatever the market thinks of the announcement itself.

Reading today's session

Concord Biotech has traded between ₹1,518.90 and ₹1,568.00 in this session against an open of ₹1,540.20 and a previous close of ₹1,560.30. That is a band of ₹49.10, or 3.15% of the current price — an ordinary day's spread, so the move is orderly rather than disorderly.

Holding above the open at ₹1,540.20 matters because it is the level intraday desks use as the session pivot: buyers who entered at the open are in profit, so there is no forced supply from that cohort.

In market-structure terms this is a continuation session, so the prior trend remains the base case until a level breaks.

The headlines behind this post

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Concord Biotech 1:1 bonus issue: Jhunjhunwala family-backed pharma stock gains 50% in 6 months, check record date detail — Livemint

How the stock has performed

What the returns table is saying

Over the last week Concord Biotech has gained +5.93% and over the month -0.70%. The two horizons pointing in opposite directions is the signature of a counter-trend move — the shorter reading is either an early turn or a pullback inside the bigger trend, and volume is what separates the two.

The twelve-month return of -3.95% is the context long-term holders judge the stock on. A moderate one-year move means the stock has broadly tracked its earnings path rather than being re-rated in either direction.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹987 to ₹1,668. The current level is 84% of the way through that band, 6.43% below the 52-week high and 58.09% above the 52-week low. Trading this close to the yearly high means there is little overhead supply from earlier buyers, which is why breakouts here tend to extend — but it also leaves no cushion if the news flow turns.

Traded quantity of 1,47,508 shares is 0.96x the 20-day average of 1,53,100. Turnover close to the recent norm suggests an orderly session rather than a scramble, so the move reflects ordinary two-way flow.

What to watch next

For this corporate action story specifically, watch the record date and the ex-date, since buying after the ex-date does not carry entitlement even though the price has already adjusted. On the chart, the ₹1,568.00 high and ₹1,518.90 low of the last session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of that low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 1,53,100 shares to be read as positioning rather than a squeeze.

So what should shareholders do with this?

For a trader, this is a low-information session: the move sits inside the stock's normal daily spread, so there is no edge in chasing it. Waiting for a close outside ₹1,518.90–₹1,568.00 is the cheaper way to be positioned.

For a long-term shareholder, one session tells you very little. The stock is 6.43% off its twelve-month high, so the more useful exercise is comparing that drawdown with the change in earnings over the same period: price falling faster than profits is an opportunity, the reverse is a warning.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

Where that leaves the stock

Concord Biotech is being bought on a corporate-action story, and at ₹1,560.30 the move is not yet backed by turnover above its own average, which is the version of a rally that tends to fade. The day's ₹1,518.90–₹1,568.00 band is the frame for the next session, and the record date and the ex-date is what resolves the story either way.

Where to track CONCORDBIO next

Live price, charts and technicals stay on the Concord Biotech stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Concord Biotech share price today?

Concord Biotech (CONCORDBIO) last traded at ₹1,560.30, +27.90 (+1.79%) against the previous close of ₹1,560.30, read from the NSE board at the close of the last trading session on Wednesday, 23 September 2026.

Why is Concord Biotech in the news today?

1 business publisher ran headlines on the company in the last session — a corporate action story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of CONCORDBIO?

Over the last twelve months CONCORDBIO has traded between a low of ₹987 and a high of ₹1,668, computed from the adjusted daily series.

Is CONCORDBIO up or down today?

CONCORDBIO gained +1.79% in the last session, trading between ₹1,518.90 and ₹1,568.00 against an open of ₹1,540.20.

Is the market open right now?

No. The market is closed at the time of writing (Wednesday, 06:05 pm IST); the levels below are the close of the Wednesday, 23 September 2026 session.

Key takeaways

• Last price: ₹1,560.30 (+1.79%) — higher at the time of writing
• Day range: ₹1,518.90 – ₹1,568.00
• 52-week high: ₹1,668

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Concord Biotech share price
• Concord Biotech quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Concord Biotech stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”